BFM
EGRX

Boothbay Fund Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Boothbay Fund Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,511
Closed -$1.17M – 1466
2020
Q3 		$1.17M Buy
+27,511
New +$1.2M 0.07% 383
2016
Q4 		– Sell
-3,146
Closed -$220K – 985
2016
Q3 		$220K Buy
+3,146
New +$174K 0.05% 515
2015
Q3 		– Sell
-3,122
Closed -$252K – 601
2015
Q2 		$252K Buy
+3,122
New +$203K 0.1% 259

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Boothbay Fund Management's EGRX Position: Q4 2020 in Review

Boothbay Fund Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2020, closing a stake of 27,511 shares — an estimated $1.17M sold.

Boothbay Fund Management first reported a position in EGRX in Q2 2015 and held it in 3 quarters. The position peaked at $1.17M in Q3 2020. 166 funds tracked by Wall St. Rank hold EGRX as of Q4 2020.

  • Boothbay Fund Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 27,511 Eagle Pharmaceuticals, Inc. shares in Q4 2020, an estimated $1.17M.
  • Boothbay Fund Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 3 quarters.
  • Boothbay Fund Management's Eagle Pharmaceuticals, Inc. position peaked at $1.17M in Q3 2020.
  • 166 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2020.

Based on Boothbay Fund Management's 13F filing for Q4 2020, filed 12 Feb 2021.